{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:59Z","timestamp":1787008979919,"version":"build-2736575974"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to explore the incidence of adverse events (AEs) reported by patients when initiating medicinal cannabis treatment for chronic pain, and the association of cannabis constituents, dose and concomitant medicines with AE incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient demographics, cannabis products and AE data were collected as part of the Cannabis Access Clinics Observational Study, and concomitant medicines were obtained from patient health summaries provided by referring doctors. Cannabis products were grouped by their constituents as either cannabidiol-only or containing both cannabidiol and \u0394-9-tetrahydrocannabinol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>From a total of 275 patients, each had a median of six concomitant medicines, with opioids (n = 179; 65%) the most common. A total of 35.6% patients took 10 or more other medicines, and they were associated with a 3.6 times higher likelihood to report the AE of fatigue (P = 0.048). Patients who received concomitant gabapentinoids were 2.4 times more likely to report dizziness (P = 0.036), patients on tricyclic antidepressants were 1.8 times more likely to report somnolence (P = 0.034) and 3.4 times more likely to report anxiety (P = 0.04), when compared with patients who were not prescribed those classes of medications. Those patients who were prescribed products containing both cannabidiol and \u0394-9-tetrahydrocannabinol were 1.5 times more likely (P = 0.004) to have experienced an AE when compared with those prescribed only cannabidiol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings show that certain concomitant medications and cannabis constituents may be associated with AE incidence when initiating medicinal cannabis. These potential pharmacokinetic and pharmacodynamic interactions require further study to develop guidance for prescribers and pharmacists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riac073","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T10:41:54Z","timestamp":1663152114000},"page":"70-79","source":"Crossref","is-referenced-by-count":10,"title":["Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-0001","authenticated-orcid":false,"given":"Elise A","family":"Schubert","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , NSW, 2006 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Johannes C","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , NSW, 2006 , Australia"},{"name":"Westmead Hospital , Westmead, NSW, 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masego T","family":"Johnstone","sequence":"additional","affiliation":[{"name":"George Clinical , Newtown, NSW, 2042 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Barlow","sequence":"additional","affiliation":[{"name":"Applied Cannabis Research , Sydney, 2000 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0505-1363","authenticated-orcid":false,"given":"Nial J","family":"Wheate","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, The University of Sydney , NSW, 2006 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/204946370900300102","article-title":"The cost and burden of chronic pain","volume":"3","author":"Phillips","year":"2009","journal-title":"Rev Pain"},{"key":"2023031318081567700_","first-page":"S1","article-title":"Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy","volume":"3","author":"Merskey HaB","year":"1986","journal-title":"Pain Suppl"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/JPR.S303186","article-title":"Chronic pain: what does it mean? A review on the use of the term chronic pain in clinical practice","volume":"14","author":"Raffaeli","year":"2021","journal-title":"J Pain Res"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00296-016-3481-8","article-title":"An overview of treatment approaches for chronic pain management","volume":"37","author":"Hylands-White","year":"2017","journal-title":"Rheumatol Int"},{"key":"2023031318081567700_","first-page":"982","article-title":"Weighing the risks and benefits of chronic opioid therapy","volume":"93","author":"Lembke","year":"2016","journal-title":"Am Fam Physician"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2018.0899","article-title":"Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial","volume":"319","author":"Krebs","year":"2018","journal-title":"JAMA"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2020.052","article-title":"Prescribing medicinal cannabis","volume":"43","author":"Arnold","year":"2020","journal-title":"Aust Prescr"},{"key":"2023031318081567700_","first-page":"539","article-title":"Cannabis and cannabinoids: pharmacology and rationale for clinical use","volume":"3","author":"Pertwee","year":"1999","journal-title":"Pharmacol Commun"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.31128\/AJGP-02-21-5845","article-title":"primer on medicinal cannabis safety and potential adverse effects","volume":"50","author":"Arnold","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780199662685.001.0001","volume-title":"Handbook of Cannabis","author":"Pertwee","year":"2014"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vu\u010dkovi\u0107","year":"2018","journal-title":"Front Pharmacol"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","article-title":"Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action","volume":"21","author":"Di Marzo","year":"1998","journal-title":"Trends Neurosci"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol Ther"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780199662685.003.0025","article-title":"Pain.","volume-title":"Handbook of Cannabis","author":"Costa","year":"2014"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.2006.00454.x","article-title":"Anandamide: an update","volume":"21","author":"Smita","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J Biol Chem"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/can.2018.0073","article-title":"Immune responses regulated by cannabidiol","volume":"5","author":"Nichols","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cbdv.200790147","article-title":"Cannabidiol \u2013 recent advances","volume":"4","author":"Mechoulam","year":"2007","journal-title":"Chem Biodivers"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14740338.2017.1397128","article-title":"Drug-drug interactions as a result of co-administering \u03949-THC and CBD with other psychotropic agents","volume":"17","author":"Rong","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2174\/138945010790980303","article-title":"Opioids and cannabinoids interactions: involvement in pain management","volume":"11","author":"Desroches","year":"2010","journal-title":"Curr Drug Targets"},{"key":"2023031318081567700_","author":"The Therapeutic Goods Administration","year":"2017"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.2018.36.34_suppl.189","article-title":"Opioid dose reduction and pain control with medical cannabis.","volume":"36","author":"Bulbul","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1080\/10826084.2017.1416408","article-title":"Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain","volume":"53","author":"Sohler","year":"2018","journal-title":"Subst Use Misuse"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/00325481.2019.1685298","article-title":"Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study","volume":"132","author":"Capano","year":"2020","journal-title":"Postgrad Med J"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.108","article-title":"Cannabis in cancer care","volume":"97","author":"Abrams","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lfs.2003.09.038","article-title":"Synergistic interactions between cannabinoid and opioid analgesics","volume":"74","author":"Cichewicz","year":"2004","journal-title":"Life Sci"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"63","DOI":"10.18773\/austprescr.1996.063","article-title":"Experimental and clinical pharmacology: opioids - mechanisms of action","volume":"19","author":"Chahl","year":"1996","journal-title":"Aust Prescr"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2147\/JPR.S144963","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids","volume":"10","author":"Savelloni","year":"2017","journal-title":"J Pain Res"},{"key":"2023031318081567700_","author":"Australian Government","year":"2021"},{"key":"2023031318081567700_","author":"Australian Government","year":"2021"},{"key":"2023031318081567700_","author":"World Health Organisation","year":"2021"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2023031318081567700_","first-page":"746","article-title":"An introduction to multiplicity issues in clinical trials: the what, why, when and how","volume":"46","author":"Li","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2023031318081567700_","author":"Australian Government","year":"2019"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur J Intern Med"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/JPR.S192174","article-title":"Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry","volume":"12","author":"Ueberall","year":"2019","journal-title":"J Pain Res"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pnpbp.2018.07.017","article-title":"Overlaps in pharmacology for the treatment of chronic pain and mental health disorders","volume":"87","author":"Sutherland","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/1871527316666170413104516","article-title":"Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines","volume":"16","author":"Arellano","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjopharm.2004.09.004","article-title":"Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia","volume":"2","author":"Parsons","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/21556660.2019.1579098","article-title":"The effect of pregabalin treatment on balance and gait in patients with chronic low back pain: a retrospective observational study","volume":"8","author":"\u00c7a\u011flar Okur","year":"2019","journal-title":"J Drug Assess"},{"key":"2023031318081567700_","author":"Australian Medicines Handbook","year":"2021"},{"key":"2023031318081567700_","article-title":"Known pharmacological actions of nine nonpsychotropic phytocannabinoids","volume-title":"Handbook of Cannabis","author":"Maria Grazia Cascio RGP","year":"2014"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/bcpt.13152","article-title":"Interaction between warfarin and cannabis","volume":"124","author":"Damkier","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"e20193256","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics."},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm9040919","article-title":"Potential adverse drug events with tetrahydrocannabinol (THC) due to drug-drug interactions","volume":"9","author":"Brown","year":"2020","journal-title":"J Clin Med"},{"key":"2023031318081567700_","author":"Food and Drug Administration","year":"2017"},{"key":"2023031318081567700_","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/31\/1\/70\/49518797\/riac073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/31\/1\/70\/49518797\/riac073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T18:17:33Z","timestamp":1701022653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/31\/1\/70\/6852742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,29]]},"published-print":{"date-parts":[[2023,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riac073","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,11,29]]}}}